Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Br J Dermatol. 2022 Aug 3;187(5):692–703. doi: 10.1111/bjd.21704

Figure 2.

Figure 2

Hazard ratio estimates of developing ulcerative colitis or Crohn disease in patients with vs. without a chronic inflammatory skin disease (CISD), after propensity-score decile stratification. CI, confidence interval; py, person-years. Overall, CISD was defined as a composite of the individual conditions: psoriasis, atopic dermatitis, alopecia areata, vitiligo and hidradenitis suppurativa. Users of immunomodulators patients receiving treatment with nonbiologic immunomodulatory agents (methotrexate, ciclosporin, mycophenolate mofetil, azathioprine, sulfasalazine, leflunomide), biologic immunomodulatory agents (dupilumab, risankizumab-rzaa, tildrakizumab, ixekizumab, secukinumab, guselkumab, ustekinumab, abatacept, adalimumab, etanercept, golimumab, certolizumab, infliximab, rituximab, anakinra, tocilizumab) or targeted synthetic immunomodulatory agents (tofacitinib, baricitinib).